The rise of Sildenafil initially fueled a period of growth for pharma, nevertheless recent shifts present a murky outlook for shareholders. Lower-cost alternatives are eroding profits, and ongoing legal battles add https://dillanzfyq303754.blogoxo.com/41567605/the-blue-pill-and-the-pharmaceutical-industry-a-risky-investment